External Link

You are now leaving the Grünenthal (IE) website. You will be re-directed to an external website. Grünenthal Pharma Ltd., Ireland accepts no responsibility for the content of other websites.

Grünenthal presence in Ireland

About Grünenthal Pharma Ltd.

Grünenthal Pharma Ltd., Ireland, a wholly owned subsidiary of Grünenthal GmbH, was established in 2005. With headquarters in Dublin, the company distributes and markets pain and anti-infective products under an exclusive distribution agreement with Grünenthal GmbH to GPs, hospital doctors, pharmacists, and nurses.

Grünenthal Pharma Limited markets: Palexia Film Coated Tablets®, Palexia SR®, Qutenza®, Vimovo®, Nexium®, Versatis®, Zomig, Ixprim®, Ixprim Effervescent®, Zydol® (tramadol HCI) and Zydol SR®.

The company includes Regulatory, Medical Information, Sales, and Marketing divisions and Market Access and Medical Science Liaison teams.

Ireland
 Ireland

Grünenthal Pharma Ltd.
4045 Kingswood Road,
Citywest Business Park, Citywest, Co. Dublin
Ireland

+44 800 254 5540
GeneralenquiresIE@grunenthal.com

Global Company Background 

Grünenthal is a global company based in Aachen, Germany, with affiliates in 28 countries across Europe, Latin America, and the US. Our products benefit patients in around 100 countries worldwide. 

As a family-owned business, we have been delivering innovative medicines for over 75 years, focusing on pain treatments for the past five decades. We aim to strengthen our leadership in this field by creating cutting-edge, non-opioid therapies. 

We cover the full value chain from research to distribution and collaborate with top scientific organizations to enhance our impact. Our company's profitable growth has been driven by acquisitions of established brands that secure our financial stability and enable investments in research. 

Grünenthal at a glance – experience our virtual company showcase

Who are we? What are we doing? How are we doing it? Our digital company overview quickly answers big questions about Grünenthal.
Read about our key objectives and activities, as well as our recent business development highlights and financial performance. Get insights into our leadership team, strategy and financials, R&D & Pipeline, Product portfolio, Reliable Supply, Environmental & Societal Governance, and our Company culture and purpose.

Grünenthal Report 2025/26

Grünenthal is driven by a clear and ambitious vision: a World Free of Pain. In 2025, we made significant progress in advancing innovative medicines for patients living with pain worldwide. The Grünenthal Report is a key way we share updates on our collective projects, priorities, and progress. It provides an overview of our continued efforts to move closer to our vision.

Responsibility Report 2024

As a recognised leader in environmental, social, and governance (ESG) matters, we proactively pursue best-in-class corporate sustainability practices. This report reflects the accomplishments of our teams worldwide around our focus areas of Patient People and Planet. Discover how our shared commitment is shaping long-term value.
M-N/A-IE-03-26-0005 April 2026